Table 1.
Myocarditis case definition for surveillance of adverse events after smallpox vaccination in the United States, 200313.
Table 2.
Pericarditis case definition for surveillance of adverse events after smallpox vaccination in the United States, 200313.
Table 3.
Characteristics of two (2) published cohorts of healthy adults providing data regarding the incidence rates of myocarditis/pericarditis (MP) per 100,000 (prior to or following SPX)3.
Fig 1.
Subject enrollment, exclusions and outcomes for two prospective cohorts, post-smallpox and annual trivalent influenza vaccine.
Table 4.
Baseline demographic and clinical characteristics of smallpox (SPX) and trivalent inactivated influenza vaccine (TIV) cohorts including subjects with at least 2 visits (pre/post immunization).
Table 5.
Frequency of new onset cardiac symptoms day 4–30 after immunization with smallpox (SPX) versus trivalent inactivated influenza vaccines (TIV).
Table 6.
Characteristics of subjects with and without new onset cardiac symptoms.
Table 7.
Prospective Cases of New Onset Myocarditis/Pericarditis or cTnT Elevation Following Immunization with Either Smallpox or Trivalent Influenza Vaccine.